Neuro biotech Nido Biosciences announced closure after its lead neurological candidate failed to show benefit in a phase 2 study. The company will wind down operations after five years and discontinue development of the midstage program. The shutdown underscores the clinical risk in rare-disease neurology and the funding repricing that follows midstage disappointment. Investors and partners in the space will reassess risk models for early-stage neuro assets as a result.